Pharmaceuticals and Healthcare

• Bial
• GenIbet – Biopharmaceuticals
• HOVIONE FarmaCiencia SA
• Iberfar
• Laboratórios Azevedos
• Laboratórios Basi
• Medinfar
• Tecnimede

Agroindustry

• Ascenza Agro, SA
• Buggypower
• Nutrinveste / Sovena Group
• RAR, REFINARIAS DE AÇUCAR REUNIDAS
• Sumol + Compal

Private academic

• Escola Superior Biotecnologia UC

Public academic

• Faculdade de Ciência e Tecnologia/UNL
• Faculdade de Ciências Médicas/UNL
• Instituto de Tecnologia Química Biológica/UNL
• Reitoria da Universidade de Lisboa
• Reitoria Universidade NOVA de Lisboa

Foundations

• Fundação para a Ciência e Tecnologia
• Fundação Luso Americana para o Desenvolvimento

Public Institutions

• Instituto Nacional de Investigação Agrária e Veterinária
• Instituto Apoio Pequenas Medias Empresas Inovação

BENEFITS FOR SHAREHOLDERS

iBET’s shareholders benefit from a first-in-line access to iBET’s scientific expertise in both Health & Pharma e Food & Health divisions as well as to R&D Laboratories from the Interface and to its associated public institutions. This privileged access enables our shareholder organizations to develop R&D projects, to access existing services and to suggest new areas of development, services and competences.

Shareholder organizations have access to:

1. First-in-line access to areas of expertise and their development: privilege-right;
2. Conceptual and practical trainings;
3. Auditing services – manufacturing process and quality assurance;
4. Technical and Scientific consultancy;
5. Access to and evaluation of business opportunities;
6. Ideation and development of project proposals and partnerships;
7. Development of technical reports;
8. Use of “Access Fee” rights to enable and expand the collaboration axes Partner – iBET.

For more information please read:

TAX BENEFITS

Donations granted to iBET are considered as expenses under the scientific patronage, as foreseen in the Tax Benefits Statute (Art. 62º A do Estatuto dos Benefícios Fiscais) as a result from its status of private non-profit research organization in the scientific area. (Despacho nº 8993/2013, Diário da República, 2ª série).

SIFIDE II, a system of tax incentives for entrepreneurial R&D is in force until 2020, as per the Investment Tax Code, approved by the Decree-Law nº 162/2014. According to that system all the costs related to R&D activities supplied by R&D institutions are eligible expenses for the purpose of that incentive. iBET fully qualifies as a R&D institution for the purpose of this incentive scheme.

INTELECTUAL PROPERTY POLICY

In research work carried out with companies, the ownership is often attributed to companies, with iBET and the inventors collecting royalties. For patents filed directly by iBET, we try to market them as soon as they are filed with relevant companies as these can better use them in their business activities.